Jubilant Pharmova Launches Advanced Sterile Fill & Finish Line, Boosting Spokane Facility Capacity

Jubilant Pharmova Limited has officially launched a new sterile fill and finish manufacturing line at its Spokane facility in Washington state, marking a significant advancement in its injectable pharmaceutical production capabilities. The expansion is part of a comprehensive $285 million investment to enhance sterile injectable manufacturing capacity and meet increasing demand from government health agencies and commercial clients.

The new sterile line incorporates cutting-edge isolator technology enabling fully aseptic processing without human contact, ensuring product sterility, safety, and compliance with stringent regulatory standards. Operating at a fast speed of 400 vials per minute, the system features 100% weight checking and dual lyophilizers, allowing versatile production including critical vaccines such as live, mRNA, and inactivated types.

This expansion aligns with Jubilant HollisterStier's strategic partnership with US government agencies through cooperative agreements totaling nearly $150 million, supported by the American Rescue Plan. The collaboration aims to boost domestic manufacturing resilience and pandemic preparedness by increasing reliable injectable manufacturing capacity within the United States.

Major Takeaways:

The Spokane facility now houses two new stainless steel sterile fill and finish lines, each coupled with dual lyophilizers to handle a wide range of injectable products and vaccines.

The investment project is scheduled to have the first line operational by fiscal year 2026, with the second line commencing commercial production by 2028.

Around 450 new jobs are expected to be created, contributing to the local Spokane economy and workforce development.

The facility meets rigorous regulatory standards from the US FDA and Health Canada, serving over 30 North American clients.

The sterile filling capacity increase translates to an additional 55 million units per year per line, significantly boosting production throughput.

This initiative reinforces Jubilant Pharmova’s commitment to enhancing the US pharmaceutical supply chain's security and reducing reliance on foreign imports.

The Spokane expansion is part of a broader plan to cement Jubilant Pharmova as a leading mid-sized sterile injectable contract manufacturer in North America.

Through this facility upgrade, Jubilant Pharmova is poised to meet rising demand for high-quality sterile injectables and vaccines in North America while driving innovation, quality, and supply chain robustness.

Sources: Jubilant Pharmova Limited Press Release, Jubilant HollisterStier Official Announcements, US Government Cooperative Agreements, American Rescue Plan Funding Information